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OBJECTIVE: The present study aimed to investigate the mechanisms underlying the anti-inflammatory and anti-
angiogenic effects of ethyl-p-methoxycinnamate isolated from Kaempferia galanga.
METHODS: The anti-inflammatory effects of ethyl-p-methoxycinnamate were assessed using the cotton pellet
granuloma assay in rats, whereby the levels of interleukin-1 and tumor necrosis factor-a were measured in the
animals’ blood. In addition, the levels of interleukin, tumor necrosis factor, and nitric oxide were measured in
vitro using the human macrophage cell line (U937). The analgesic effects of ethyl-p-methoxycinnamate were
assessed by the tail flick assay in rats. The anti-angiogenic effects were evaluated first by the rat aortic ring assay
and, subsequently, by assessing the inhibitory effects of ethyl-p-methoxycinnamate on vascular endothelial
growth factor, proliferation, migration, and tube formation in human umbilical vein endothelial cells.
RESULTS: Ethyl-p-methoxycinnamate strongly inhibited granuloma tissue formation in rats. It prolonged the
tail flick time in rats by more than two-fold compared with the control animals. The inhibition of interleukin
and tumor necrosis factor by ethyl-p-methoxycinnamate was significant in both in vivo and in vitro models;
however, only a moderate inhibition of nitric oxide was observed in macrophages. Furthermore, ethyl-p-
methoxycinnamate considerably inhibited microvessel sprouting from the rat aorta. These mechanistic studies
showed that ethyl-p-methoxycinnamate strongly inhibited the differentiation and migration of endothelial
cells, which was further confirmed by the reduced level of vascular endothelial growth factor.
CONCLUSION: Ethyl-p-methoxycinnamate exhibits significant anti-inflammatory potential by inhibiting pro-
inflammatory cytokines and angiogenesis, thus inhibiting the main functions of endothelial cells. Thus, ethyl-
p-methoxycinnamate could be a promising therapeutic agent for the treatment of inflammatory and
angiogenesis-related diseases.
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& INTRODUCTION
Inflammatory reactions involve the activation of a
number of different intra-cellular pathways that lead to
the induction of specific pro-inflammatory genes, including
those encoding interleukin-1 (IL-1) and tumor necrosis
factor-a (TNF-a). For instance, the attachment of a bacterial
antigen to the toll-like receptors on the surface of macro-
phages and dendritic cells results in the activation of the
mitogen-activated protein kinase pathway (MAPK/NF-kB
pathway), which leads to the induction of pro-inflammatory
genes encoding IL-1, TNF-a, cyclooxygenase-2 (COX-2), and
Copyright  2014 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
No potential conflict of interest was reported.
DOI: 10.6061/clinics/2014(02)10
BASIC RESEARCH
134
inflammatory nitric oxide (iNO) (1). The release of IL-1 and
TNF-a from the activated macrophages results in the further
activation of immune cells that are in close proximity. This,
in turn, provokes a positive feedback loop that promotes the
synthesis of cytokines by the activated immune cells, thus
aggravating the inflammatory reaction. iNO release leads
to vasodilation in the vessels of the affected areas, thus
facilitating the increased blood flow to the affected areas. In
contrast, TNF-a induces the expression of attachment
molecules, such as E-selectin, intercellular adhesion mole-
cule-1 (ICAM-1), and vascular cell adhesion molecule
(VCAM-1), on the surface of vascular endothelial cells (2-
4). The circulating macrophages attach to the surface of the
endothelial cells with the help of selectins, ICAM-1, and
VCAM-1. The attached macrophages invade through the
vascular walls and reach the affected site to engulf the
invading bacteria. Together, all these factors cause inflam-
mation in the affected area, which is manifested by redness
and swelling (edema) due to the increased blood flow and
permeability of vessels. Most of the phytoconstituents that
are known to exert anti-inflammatory effects have been
studied extensively for their potential to inhibit these pro-
inflammatory cytokines (5,6). Accordingly, such investiga-
tions are mandatory for the mechanistic evaluation of newly
reported anti-inflammatory constituents.
Kaempferia galanga is a valuable medicinal herb that is
known for a number of its medicinal properties worldwide,
particularly in Malaysia and Thailand (7,8). The herb has
potential anti-inflammatory, analgesic, mosquito-repellent,
larvicidal, nematicidal, vasorelaxant, and pro-apoptotic
activities. The herb has been used for decades in traditional
medicine in the management and treatment of swelling and
pain, such as headaches, toothaches, stomachaches, and
rheumatism (9). The crude extract of K. galanga has already
been reported to possess anti-inflammatory and analgesic
properties (9,10). However, the constituents responsible for
these properties and the mechanisms underlying these
properties have not been evaluated. In a recent study, we
reported that the anti-inflammatory effect of K. galanga is
mainly due to its active constituent, ethyl-p-methoxycinna-
mate (EPMC) (8). This was the first report on the anti-
inflammatory effect of EPMC isolated from K. galanga.
EPMC has been reported to have anti-tuberculosis (11),
nematicidal (12,13), mosquito-repellent (14,15), larvicidal,
antineoplastic, and anti-microbial potentials (7). Moreover,
in an in vitro colorimetric assay, EPMC has been shown to
inhibit the enzymatic activity of COX-1 and COX-2 in a cell-
free system (8). In a recent study, the inhibitory effect of
EPMC and its thiourea derivatives in a mouse fibrosarcoma
model was reported (16). However, few scientific data
validating the anti-inflammatory effects of EPMC in a
chronic in vivo model are available, and its inhibitory action
on pro-inflammatory cytokines has not yet been reported.
Thus, the aim of the present study was to investigate the
effect of EPMC in a sub-chronic in vivo model, particularly
its inhibitory effect on potential cytokines. In a previous
report, the inhibitory effect of EPMC on COX-1 and COX-2
encouraged the authors to focus on assessing its possible
analgesic effect using an in vivo model. The inhibitors of
cytokines, particularly TNF-a, have been shown to possess
strong anti-angiogenic potential (12-14). Additionally, the
inhibition of TNF-a synthesis has been shown to prevent the
activation of the NF-kB pathway, which is necessary for the
synthesis of angiogenic proteins (17-19). Therefore, the aim
of this study was to further extend this knowledge and
evaluate the possible anti-angiogenic effects of EPMC, with
a primary focus on investigating its probable mechanism of
action.
& MATERIALS AND METHODS
Chemicals and equipment
The 1H-NMR Bruker 500-MHz Ultrashield (Billerica,
Massachusetts, USA), TECAN Multi-mode microplate
reader Model Infinite 200 (Mannedorf, Switzerland), and
Buchi Rotavapor Model R-210/215 (Flawil, Switzerland)
were used. The tail flick analgesia meter was purchased
from IITC Life Sciences, CA, USA. Methylthiazolyldiphenyl-
tetrazolium bromide reagent (MTT), Salmonella abortus
lipopolysachharide (LPS), dimethyl sulfoxide (DMSO),
phosphate-buffered saline (PBS), suramine, and penicillin/
streptomycin (PS) solution were purchased from Sigma-
Aldrich, Germany. Human IL-1, human TNF-a, human
nitric oxide (NO), human vascular endothelial growth factor
(VEGF), rat IL-1, and rat TNF-a ELISA kits were purchased
from Cusabio, China. RPMI 1640, human umbilical vein
endothelial cells (HUVEC), and endothelial cell medium
(ECM) supplied with endothelial cell growth supplements
(ECGS) were obtained from ScienCell, USA. Trypsin and
heat-inactivated fetal bovine serum were purchased from
GIBCO, UK. Matrigel matrix (10 mg/ml) was obtained from
SABiosciences, USA. All other chemicals used in this study
were analytical-grade or better.
Isolation of ethyl-p-methoxycinnamate (EPMC)
from Kaempferia galanga
In our recent study, EPMC was isolated from the active
sub-fraction of a chloroform extract of K. galanga (8), and the
yield was low (0.026%). However, in the current study, the
yield was increased to 1.04% using petroleum ether. The
dried and powdered rhizomes (3 kg) were extracted with
petroleum ether (4 l) in a Soxhlet apparatus at 40 C˚ until the
solvent in the Soxhlet column was nearly transparent. The
extract was filtered, concentrated in a vacuum evaporator
(Buchi Rotavapor Model R-210, Flawil, Switzerland) at 25 C˚,
and freeze-dried. The dried extract (124 g) was carefully
washed with n-hexane without stirring. The n-hexane
supernatant was then decanted, and fresh n-hexane was
added until the solvent was almost transparent. The residue
that remained after washings consisted of pale yellow,
needle-like crystals, which were collected in n-hexane in a
conical flask, and a 153 hexane-chloroform mixture was
added drop-wise until the crystals completely dissolved.
The solvent was allowed to evaporate slowly at room
temperature, yielding pure crystals of EPMC (31.2 g). The
compound had a sharp melting point of 49 C˚, as observed
using a Toshniwal melting point apparatus. The molecular
structure was elucidated using the nuclear magnetic
resonance (NMR) spectroscopic technique [1H NMR
(500 MHz, CDCl3) d: 1.32 (3H, t, 16CH3, J= 7.5 Hz), 3.82
(3H, s, 16OCH3), 4.25 (2H, q, 16CH2), 6.31 (1H, d,
J= 16.0 Hz, 16CH alkene), 6.90 (2H, d, J= 7.0 Hz, 26CH
benzylic), 7.42 (2H, d, J= 7.0 Hz, 26CH benzylic), 7.65 (1H, d,
J= 16.0 Hz, 16CH alkene); 13C {1H} NMR (125.1 MHz,
CDCl3) d: 14.5 (CH3), 55.3 (OCH3), 60.3 (CH2), 114.3
(benzylic CH2), 115.7 (CH alkene), 127.3 (Ar-C), 129.7(Ar-
C), 144.2 (CH alkene), 161.3 (Ar-C), 167.3 (carbonyl C)].
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Evaluation of pharmacological activities
Animals. Male Sprague Dawley (SD) rats (200 to 250 g)
were obtained from the Animal Research and Service Centre
(ARSC), Universiti Sains Malaysia. The animals were kept in
the animal transit room, School of Pharmaceutical Sciences,
Universiti Sains Malaysia, at 23 C˚ and 40-60% relative
humidity in a 12-hour dark/light cycle. The experimental
procedures were also performed in the same room. The
animals were provided free access to water and food.
However, food was withdrawn 12 hours before any
experimental procedure was performed on the animals.
The experimental procedure and the use of animals were
approved by the Animal Ethics Committee of Universiti
Sains Malaysia before the commencement of the experi-
ments [Reference number: PPSG/07 (A)/044/(2011) (63)/;
Approval number: USM/Animal Ethics Approval/2010/
(63) (270)].
In vivo cotton pellet granuloma assay
The anti-inflammatory effect of EPMC was evaluated
using the cotton pellet granuloma assay in rats, as
described by Anosike and co-workers (20), with minor
modifications. Briefly, rats were anaesthetized with an
intra-peritoneal administration of pentobarbitone sodium
(60 mg/kg). Two pouches were created using scissors, one
on either side of the ventral abdominal area of each rat
under the loosened skin, and a pre-autoclaved cotton
pellet with a weight of 30 mg was implanted in each
pouch. Thereafter, the pouches were stitched closed using
surgical silk. Twenty-four hours after the implantation of
the cotton pellets, the rats were given EPMC in three
doses, specifically, 200, 400, and 800 mg/kg, once daily for
7 days through oral gavage. Reference group rats were
given indomethacin (5 mg/kg) and dexamethasone
(7 mg/kg), and negative control rats were given 1% tween
80. On the 8th day, the animals were anaesthetized by
pentobarbitone sodium administration (60 mg/kg), and
3 ml of blood was withdrawn from each rat by cardiac
puncture. The rats were euthanized by 100% CO2 using a
CO2 chamber, and the cotton pellets were dissected from
each rat. The pellets were dried in an oven at 40 C˚ until
they were of constant weight. The weight of each cotton
pellet was recorded, and the percent inhibition of
granuloma tissue formation was calculated using the
following formula:
% inhibition of granuloma tissue formation~
½f1- (Tt = Tc)g| 100
where Tc and Tt are the weights of the cotton pellets
from the rats in the control group and treated group,
respectively.
Enzyme-linked immunosorbant assay to measure
TNF-a and IL-1
The blood samples collected from rats on the 8th day of
the cotton pellet assay were centrifuged to obtain plasma,
which was subjected to enzyme-linked immunosorbant
assay (ELISA) for TNF-a and IL-1 assessment using rat
TNF-a and rat IL-1 ELISA kits, respectively. The procedure
was carried out according to the manufacturer’s instructions
(CUSABIO). The concentration of the respective cytokine
in each sample was calculated using a standard curve
equation. The percent inhibition of cytokine production was
calculated using the following formula:
% inhibition of cytokine production~
½f1- (ODt = ODc)g| 100
where ODt and ODc are the optical densities of the
treatment and control group samples, respectively.
In vitro cytokine inhibition assay in human
macrophage (U937) cells
Macrophage differentiation was induced in U937 human
macrophage cells by adding 5 ng/ml PMA for 3 days, as
described by Federica and co-workers (21). The cells were then
starved overnight and activated to synthesize cytokines andNO
by the addition of 5 ng/ml of Salmonella abortus LPS. Five
concentrations of EPMC, namely, 200, 100, 50, 25, and 12.5 mg/
ml, were added in the presence of PMA (5 ng/ml). The cells
were incubated at 37 C˚ for 48 hours in a CO2 incubator. The
plate was then centrifuged and the cell culture supernatants
were subjected to ELISA for TNF-a, IL-1, and NO assessment
using human cytokine and NO ELISA kits according to the
manufacturer’s instructions. The percent inhibition of cytokine
production was calculated using the following formula:
% inhibition of cytokine production~
½f1- (ODt = ODc)g| 100
whereODt andODc are the optical densities of thewells of cells
treated and not treated with EPMC, respectively.
The median inhibitory concentration (IC50) of EPMC in
inhibiting cytokine synthesis was determined by nonlinear
regression analysis of log-concentration-response curves.
Evaluation of analgesic activity of
ethyl-p-methoxycinnamate
The analgesic effect of graded doses of EPMC was evaluated
using the rat tail flick assay, as described by Dableh and co-
workers (22), with minor modifications. A radiant heat source
was used in this assessment. Light from the projector bulb of the
analgesiometer was focused on the skin of the rat, at a distance of
approximately 5 cm from the distal end of the tail. The area of the
skin was blackened to facilitate maximum light absorption. The
time taken by the rats to withdraw their tail was measured by a
timer that was set to switch off automatically as soon as the rat
moved its tail away from the light beam. The intensity of lightwas
set to achieve a baseline time of 10-12 seconds. Each reading was
taken 3 times, with a standard deviation of less than 10%. The
animals were divided into five groups (n=6). Groups 1, 2, and 3
were orally administered EPMC at a dose of 200, 400, and
800 mg/kg, respectively, whereas group 4 was given codeine
phosphate (30 mg/kg). Group 5 rats were given 1% tween 80.
The tail flick time for each rat was measured 30, 60, and 90
minutes after the administration of EPMC.An increase in the time
taken by the rats to flick their tail away from the light beam was
taken as ameasure of the analgesic activity of EPMC. The percent
inhibition of pain was calculated by the following formula:
% inhibition of pain~ ½f1 (FTt = FTt)g| 100
where FTt is the tail flick time recorded in treatment group rats
and FTc is the tail flick time recorded in control group rats.
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Assessment of the anti-angiogenic effect
Ex vivo rat aortic ring assay
The anti-angiogenic effect of EPMC was evaluated in vitro
in rat aortic rings, as previously described (23). Briefly, two
layers of cell culture medium, layer 1 (L1) and layer 2 (L2),
were prepared. L1 contained 25 ml of M199 basal medium
supplemented with fibrinogen (3 mg/ml), aprotinin (5 mg/
ml), and L-glutamine (1% w/v). L2 contained 25 ml of M199
medium supplemented with FBS (20% v/v), L-glutamine
(2 mM), aminocaproic acid (1 mg/ml), amphotericin B
(2.5 mg/ml), and gentamicin (60 mg/ml). EPMC was added
to L2 in 4 concentrations, specifically, 200, 100, 50, and
25 mg/ml. The thoracic aorta was dissected from each rat
and placed in M199 medium in a petri dish. The tissue
was cleaned of adipose tissue and cut into thin rings of
approximately 1-mm thickness. Then, 500 ml of L1 was
added to each well of a 48-well tissue culture plate, and 1
ring was placed in each well of the plate. Next, 10 ml of
thrombin (50 NIH U/l) was added to each well, and after 90
minutes of incubation at 37 C˚ and 5% CO2, 500 ml of L2 was
overlaid on L1 in each well. After 4 days of incubation at
37 C˚ and 5% CO2, the top layer, L2, was replaced with fresh
L2 containing EPMC. On day 5, images of aortic rings were
taken using an AMG EVOS f1 inverted microscope (406
magnification), and the growth of the sprouting blood
vessels was quantified using Leica QWin software (Grand
Island, NY, USA), as previously reported (24). Briefly, the
distance of growth between at least 20 growth points was
measured in each ring. The results were presented as the
mean percent inhibition of five independent experiments.
Dimethyl sulfoxide (DMSO) was used as a negative control,
and suramin 100 mg/ml was used as a reference drug. The
percent inhibition of blood vessels was calculated using the
following formula:
% inhibition of blood vessels = [1-(Ao/A)]6100
where Ao is the length of blood vessel in treated rings in mm
andA is the length of vessels in the control group. The IC50 of
EPMC in inhibiting vascular growth was calculated from a
linear regression equation obtained from a dose-response
curve. Based on the results of this assay, the anti-angiogenic
property of EPMC was subjected to further study.
Anti-proliferation assay in HUVECs
Human umbilical vein endothelial cells (HUVECs) were
used as a model cell line for angiogenesis. The cells were
harvested by trypsinization and re-suspended in 5 ml of
fresh medium. The cell count was adjusted to 1.56105/ml,
and 100 ml was seeded in each well. The cells were allowed
to attach overnight. Then, an additional 100 ml of fresh
medium containing EPMC in 6 different concentrations,
specifically, 200, 100, 50, 25, 12.5, and 6.25 mg/ml, was
added, and the cells were further incubated at 37 C˚ and 5%
CO2 for 48 hours. The viability of the cells was then assessed
by the MTT assay, as described previously (23). The percent
inhibition was calculated using the following formula:
% inhibition of cells
~ 1{ absorbance of sample{ blankð Þ½ =
absorbance of negative control{ blankð Þ| 100:
Tube formation assay
The ability of EPMC to inhibit the formation of tube-
like structures by HUVECs was evaluated in vitro in a
Matrigel matrix, as described previously (23). Briefly,
HUVECs were treated for 24-48 hours with three con-
centrations of EPMC, specifically, 200, 100, and 50 mg/
ml. On the day of the experiment, Matrigel stock
solution (10 mg/ml) was diluted at 152 v/v in ice-cold,
serum-free ECM. Then, 150 ml of the diluted Matrigel
solution was added to each well of a 48-well culture
plate. The gel was allowed to solidify for 45 minutes at
37 C˚ in 5% CO2. After 6 hours, the tube-like structures
were examined under light microscopy at 46magnifica-
tion. Images of each well were taken using an AMG
EVOS fI inverted microscope at 46 magnification, and
the length and width of the tube-like structures were
quantified using the ScnImage software package. The
results are presented as the mean percent inhibition of
five replicates.
Determination of VEGF levels in HUVECs
HUVECs were seeded in endothelial cell medium at a
concentration of 16106 in a 6-well culture plate. After they
had been allowed to attach overnight, the HUVECs were
treated for 6 hours with EPMC at 3 different concentrations,
specifically, 200, 100, and 50 mg/ml. The concentration of
human VEGF 165 in the HUVEC lysate was estimated using
a human VEGF ELISA kit (CUSABIO, China), according to
the manufacturer’s instructions.
Cell migration assay
The ‘‘scratch’’ wound assay was used to assess the
effect of EPMC on HUVEC cell migration and was
performed as described by Doleckova and co-workers
(25). HUVEC cells were seeded in 6-cm dishes, and the
cell monolayer was scraped with a disposable rubber
policeman to create a cell-free zone. The cells were
incubated overnight in M199 medium supplied with 3
concentrations of EPMC, specifically, 200, 100, and 50 mg/
ml. Images of 6-8 microscopic fields were taken at the 0,
6th, and 12th hour of incubation using an AMG EVOS fI
inverted microscope (46magnification). The area of the
cell-free zone was measured using Leica QWin software,
and the percent of wound closure was calculated using
the following formula:
% wound closure~
1{ the width at the indicated times = the width at time zeroð Þ½ 
| 100
The results are presented as the percent of wound closure
(n = 6).
Statistical analysis
Significant differences between the treatment and control
groups were evaluated by one-way analysis of variance
(ANOVA), followed by Tukey’s multiple comparison test.
Differences were considered significant at p,0.05, p,0.01,
and p,0.001.
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& RESULTS
Ethyl-p-methoxycinnamate inhibits granuloma
tissue formation
Figure 1A shows the mean dry weight of the cotton
pellets dissected from the rats treated with graded doses of
EPMC. At the doses of 200, 400, and 800 mg/kg, EPMC
inhibited granuloma tissue formation by 38.98, 44.21, and
51.65% (p,0.001), respectively. The results were comparable
with those derived from standard reference drugs. The
percent inhibition of granuloma tissue formation by
indomethacin (5 mg/kg) and dexamethasone (7 mg/kg)
was found to be 54.35 and 69.12% (p,0.001), respectively.
Anti-analgesic effect of ethyl-p-methoxycinnamate
Figure 1B shows the percent delay in the tail flick time
recorded in treatment group rats with respect to the control
group rats. EPMC delayed the tail flick time up to 37, 125.6,
and 159.1% at the doses of 200, 400, and 800 mg/kg,
respectively (p,0.001). In comparison, the standard refer-
ence drug prolonged the tail flick response up to 204.6%.
In vivo inhibitory effect of EPMC on cytokine
production
Figure 1C shows the mean concentrations of IL-1 and
TNF-a in the blood samples of the rats used in the cotton
pellet assay. The concentration of IL-1 in the blood was
Figure 1 - A) The mean weight of cotton pellets dissected from rats treated with ethyl-p-methoxycinnamate (EPMC) at doses of 200,
400, and 800 mg/kg. B) Percent increase in the time taken by rats to flick their tail away from heat, a measure of the analgesic effect of
EPMC, at doses of 200, 400, and 800 mg/kg. C) Blood concentration of interleukin-1 (IL-1) and tumor necrosis factor-a (TNF-a) in rats
treated with EPMC at doses of 200, 400, and 800 mg/kg on the 8th day of the cotton pellet granuloma assay. D) Percent inhibition of
IL-1, TNF-a, and nitric oxide (NO) synthesis by EPMC in U937 cells at concentrations of 25, 50, 100, and 200 mg/ml. The cell culture
supernatants were collected after 48 hours and subjected to an enzyme-linked immunosorbant assay (ELISA) for the assessment of IL-1,
TNF-a, and NO. All values are represented as the mean ¡ SEM (n=6), and *, **, and *** indicate significant differences of p,0.05,
p,0.01, and p,0.001, respectively, compared with the control-treated group.
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lowered by EPMC administration in a dose-dependent
manner. The highest concentration of IL-1, 25.81 pg/ml,
was found in the blood of negative-control rats, and the
concentration of IL-1 in the blood samples of rats treated
with 200, 400, and 800 mg/kg of EPMC was estimated to
be 22.88, 20.42, and 16.09 pg/ml, respectively. The lowest
concentration, 9.74 pg/ml, was recorded in the blood
samples of indomethacin-treated rats. The median effective
dose (ED50) of EPMC for the inhibition of IL-1 in vivo was
estimated to be 1.079 g/kg. EPMC inhibited the synthesis of
IL-1 by 11.35, 20.9, and 37.67% at the doses of 200, 400, and
800 mg/kg, respectively. However, the synthesis of IL-1
was inhibited by 62.25% by indomethacin.
The concentration of TNF-a in the blood samples of the
control group rats was 35.85 pg/ml. Its concentration in
rats treated with 200, 400, and 800 mg/kg of EPMC was
estimated to be 27.09, 22.25, and 15.27 pg/ml, respectively.
At 800 mg/kg, EPMC exhibited a more pronounced activity
than that of the standard reference drug, indomethacin
(16.51 pg/ml). EPMC inhibited the synthesis of TNF-a by
24.43, 37.95, and 57.40% at the doses of 200, 400, and
800 mg/kg, respectively.
In vitro inhibitory effect of EPMC on cytokine
production in human macrophages
EPMC reduced the concentration of IL-1 in U937 cells in
a dose-dependent manner. Figure 1D shows the percent
inhibition of IL-1, TNF-a, and NO in macrophages by
EPMC. The percent inhibition of IL-1 by 25, 50, 100, and
200 mg/ml of EPMC was estimated to be 18.09, 29.23, 39.84,
and 55.04%, respectively, and the IC50 was 166.4 mg/ml. A
strong inhibition of TNF-a (64.11%) was observed at the
lowest concentration of EPMC (25 mg/ml) in vitro, and
increasing doses further decreased the concentration of
TNF-a in a dose-dependent manner. The percent inhibition
of TNF-a at concentrations of 50, 100, and 200 mg/ml of
EPMC was 53.25, 48.76, and 35.71%, respectively, and the
IC50 was 96.84 mg/ml. The inhibitory effect of graded doses
of EPMC on nitric oxide production was not very efficient.
At the low dose of 25 mg/ml, the percent inhibition of NO
synthesis was only 12.4%. The percent inhibition was
significantly reduced further (p,0.05) to 21.4, 22.2, and
23.8% at 50, 100, and 200 mg/ml EPMC, respectively.
Anti-angiogenic effects of
ethyl-p-methoxycinnamate
EPMC inhibited the sprouting of microvessels in rat aortic
explants. Compared with the control treatment, EPMC
significantly inhibited the growth of blood vessels in the
aortic rings of rats. Figure 2A shows the prominent growth
of vasculature in the untreated group (control). Figure 2B
depicts the effect of the standard reference drug, suramin,
which resulted in a 86.3% inhibition. In contrast, EPMC
exhibited a dose-dependent inhibitory effect on microvessel
formation. Figures 2C-2F show the inhibition of vascular
growth in the aortic rings treated with different concentra-
tions of EPMC. The inhibition of vessel growth by EPMC
was estimated to be 18.2, 32.89, 53, and 99.3% at the
concentrations of 25, 50, 100, and 200 mg/ml, respectively,
and the IC50 91.90 was mg/ml. Figure 2G graphically
illustrates the dose-dependent inhibition of the growth of
microvessels from rat aortas, and the graph shows that the
effect of EPMC was comparable to that of the standard
reference drug, suramin.
Ethyl-p-methoxycinnamate inhibits the
proliferation and migration of HUVECs
To investigate the possible mechanism by which EPMC
inhibits the growth of aortic blood vessels, a series of in vitro
experiments were performed to confirm the anti-angiogenic
activity of EPMC. As angiogenesis begins with the local
proliferation of endothelial cells in response to a pro-
angiogenic stimulus, we first determined the anti-prolifera-
tive effect of EPMC on human endothelial cells. At
concentrations of 12.5, 25, and 50 mg/ml, EPMC was not
cytotoxic to HUVECs. However, at concentrations of 100
and 200 mg/ml, EPMC significantly inhibited the prolifera-
tion of HUVECs by 30 and 39.1%, respectively (p,0.05),
compared with the control. The IC50 calculated for EPMC
was 160 mg/ml.
The results showed that the standard reference, vincris-
tine, exhibited a strong anti-proliferative effect, with an IC50
of 0.06 mg/ml. Figure 3A graphically summarizes the dose-
dependent inhibitory effect of EPMC on the cell viability of
HUVECs, as determined by the MTT assay.
The HUVEC migration assay is representative of the
ability of endothelial cells to form new blood vessels. The
assay is also a straightforward and economical method by
which to evaluate the migration ability of these cells (21). A
scratch wound was created on the monolayer of cells
(Figure 3B), and the effect of EPMC on the closure of the
wound was assessed. Figure 3B shows a photomicrograph
of endothelial cells migrating across the scratch wound after
6 and 12 hours of incubation. The analysis (Figure 3C)
revealed that the percent closure of wounds in untreated
cells was 93.4%. In contrast, the percent closure of wounds
in cells treated with EPMC at concentrations of 50, 100, and
200 mg/ml was 72.8, 14.77, and 1.84%, respectively.
Ethyl-p-methoxycinnamate inhibits tube formation
in HUVECs
To characterize the anti-angiogenic activity of EPMC, the
tube formation assay, a well-established, three-dimensional
in vitro angiogenesis assay, was conducted. HUVECs
were cultured on Matrigel-formed, tube-like networks
(Figure 4A) within 8 hours, reflecting, in part, the process
of angiogenesis. The effects of EPMC were more pro-
nounced than those of the standard drug, suramin, which
inhibited the formation of tube-like structures by 76.8% at a
dose of 100 mg/ml (Figure 4B). EPMC showed a dose-
dependent inhibitory effect, with 87.6 and 98.2% inhibition
observed at concentrations of 100 and 200 mg/ml, respec-
tively (Figure 4C and 4D). It is noteworthy that 100 mg/ml
EPMC completely abrogated the integrity of the endothelial
tube network, reducing the tube-like structures both in
width and length. This concentration is lower than the IC50
value of EPMC for inhibiting HUVEC proliferation. The
figure clearly shows that the endothelial cells lost their
pseudopodia-like cellular extensions and that the network
structures were disrupted following EPMC treatment.
Figure 4E depicts the dose-dependent inhibitory effect of
EPMC on the width and length of the endothelial cell tube
network.
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Figure 2 - Photomicrograph images of vascular growth in rat aortic rings, which were taken on the 5th day of the experiment using an
inverted phase-contrast microscope at 46magnification. A) Control rings are shown. B) Rings treated with suramin 100 mg/ml are
shown. C, D, E, and F) Rings treated with 25, 50, 100, and 200 mg/ml ethyl-p-methoxycinnamate (EPMC) are shown. G) Graphical
representation of the inhibitory effect of EPMC on blood vessel growth in rat aortic rings at concentrations of 50, 100, and 200 mg/ml.
The result is compared with the standard reference, suramin. All values are represented as the mean¡ SEM (n=10), and *** indicates
significant differences of p,0.001 compared with the control-treated group.
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In vitro inhibitory effect of EPMC on VEGF level in
HUVECs
The level of VEGF in treated and untreated HUVECs was
determined using a human VEGF 165 ELISA kit. EPMC
treatment caused a significant (p,0.01) decrease in VEGF
content in cell lysates compared with the control (p,0.01).
EPMC resulted in a dose-dependent reduction in VEGF
levels (Figure 4F). Specifically, at 100 mg/ml EPMC, the
VEGF level was 10.8%, and at 200 mg/ml EPMC, the level of
VEGF was further drastically reduced to 17.1%.
& DISCUSSION
In a recent study, we reported the anti-inflammatory effect
ofK. galanga (8). It has been shown that plant extracts, many of
which have potent anti-inflammatory constituents, can inhibit
inflammation by effectively suppressing the production of
granulation tissue in a rat model (26). Although EPMC, the
most dominant anti-inflammatory constituent of K. galanga,
has been found to inhibit COX-1 and COX-2 in a cell-free
system, the effects of EPMC on pro-inflammatory nitric oxide
and the cytokines IL-1 and TNF-a have not been elucidated.
Thus, this study sought to evaluate the anti-inflammatory
mechanisms of EPMC in addition to any other potential
pharmacological activities, such as analgesic and anti-angio-
genic effects. Therefore, the present study was designed to
investigate the potential inhibitory effect of EPMC on IL-1,
TNF-a, and NO in both in vitro and in vivo models.
Accordingly, the cotton pellet-induced rat granuloma assay
was conducted to evaluate the anti-inflammatory potential of
EPMC in a sub-chronic model. EPMC inhibited the formation
of granuloma tissue in a dose-dependent manner, and these
results were in agreement with those from our previous
report, thus confirming EPMC as an active principle
component of K. galanga. Moreover, the inhibition of IL-1,
TNF-a, and NO levels in macrophages suggests that EPMC
exerts its anti-inflammatory effects by suppressing the ability
ofmacrophages to produce these proinflammatorymediators.
The significantly low median inhibitory concentration
(IC50) of EPMC for IL-1, TNF-a, and NO, which was
estimated in human monocytic macrophage cells (U937),
corroborates the finding that EPMC is a potent cytokine
inhibitor. The pattern of IL-1 inhibition obtained in the in
vivomodel was similar. However, the inhibition of TNF-a in
macrophages (U-937 cell line) was found to be decreased
with increasing concentrations of EPMC. It is evident from
some previous studies that EPMC has cytotoxic and pro-
apoptotic effects in cancer cell lines (27,28). Accordingly, the
decreased inhibition of TNF-a at high doses of EPMC is
likely due to the cytotoxic effects of EPMC on U937 cells.
The analgesic effect of EPMC was evaluated by the tail
flick method in rats. Similar to its dose-dependent anti-
inflammatory effects, EPMC also significantly increased the
tail flick time in a dose-dependent manner. The suppression
of the pro-inflammatory cytokines investigated blocks the
induction of genes that encode COX-2. In addition to IL-1,
Figure 3 - The effects of ethyl-p-methoxycinnamate (EPMC) on
proliferation and migration of human umbilical vein endothelial
cells (HUVECs). A) Graphical representation of the inhibitory
effect of EPMC on the percent of viable HUVEC cells at
concentrations of 25, 50, 100, and 200 mg/ml. B) The inhibitory
effects of EPMC on cell migration in HUVECs. Images were taken
under an inverted phase-contrast microscope at 46magnifica-
tion after 0, 6, and 12 hours of incubation. Straight lines show
the width of the cell-free zone, whereas the circles represent the
sites at which the cells completely filled the gap after migration.
C) Graphical representation of the inhibitory effect of EPMC on
the migration of endothelial cells. All values are represented as
the mean ¡ SEM (n=6), and *, **, and *** indicate significant
differences of p,0.05, p,0.01, and p,0.001, respectively,
compared with the control-treated group.
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COX-2 is also necessary for the synthesis of prostaglandins
from arachidonic acid. Accordingly, blocking COX-2 synth-
esis may account for the significant analgesic effect of EPMC
that was observed. It has been reported that EPMC inhibits
the enzymatic active sites on COX-1 and COX-2 (8), which
may contribute to its analgesic effect. Although this is the first
report of an analgesic effect of EPMC, a previous report on
the analgesic effect of a water extract of K. galanga suggested
that the effect involved the opioid analgesic pathway (10).
Therefore, in addition to the inhibition of the cyclooxygenase
pathway, the analgesic effect of EPMCmay also be associated
with its regulation of the opioid pathway. However, further
investigation is required to confirm this hypothesis.
Angiogenesis has been strongly implicated in the pro-
gression of chronic inflammation (29), as it aids in the
maintenance of tissue perfusion and increases the cellular
traffic required for inflammation (30). Thus, the inhibition of
angiogenesis is a suitable target for treating chronic inflam-
matory diseases. In addition, cytokines, particularly IL-1 and
TNF-a, have been found to be produced at high levels in
rapidly growing granulation tissue (31,32), which has been
suggested to promote excessive angiogenesis (33,34). It has
been reported that macrophages enhance angiogenesis in
inflammatory granulation tissue through cytokines via the
production of VEGF (35). The present study revealed that
while EPMC suppressed the production of granulation tissue
in cotton pellets, it also significantly inhibited the production
of VEGF in human endothelial cells.
Cytokines from infiltrating macrophages play a signifi-
cant role in angiogenesis in granulation tissue (35).
Figure 4 - Effects of ethyl-p-methoxycinnamate (EPMC) on tube formation and VEGF content in HUVECs. For the tube-formation assay,
HUVECs (26104 cells/well) were plated on Matrigel-precoated 96-well plates and treated with different concentrations of EPMC for
24 hours. Phase-contrast micrographs showing the effects of EPMC and suramin on the differentiation of HUVECs are presented. A)
Control group (vehicle treated), showing that the endothelial cells grown on the three-dimensional Matrigel media differentiated into
branching structures to form capillary tube-like structures composed of multiple cells with intercellular spaces or lumens. The image
clearly shows prominent areas covered with thick cells (brackets), tubes (arrows), loops (Lo), and branching points (b). B) Treatment
with EPMC (50 mg/ml) resulted in a slight disruption of bridges (arrow head) and branching points. C) Treatment with EPMC (100 mg/ml)
caused notable disorganization in the tube-like structures. Specifically, the improper development of lumens in the cell-cell
connections can be seen. The apparent inhibitory effect of EPMC on the differentiation of HUVECs is also noticeable, and the affected
tubes and network can be clearly seen. D) Treatment with suramin (100 mg/ml) caused the complete abrogation of the bridges in the
tube-like structures, which is evident by the absence of cell-covered areas (brackets in Figure A), tubes, and branching points. E)
Graphical depiction of the dose-dependent inhibitory effect of EPMC on the height and width of the capillary-like structures in
HUVECs. F) Graphical representation of the percent inhibition of vascular endothelial growth factor (VEGF) level in HUVEC lysates by
EPMC. All values are represented as the mean ¡ SEM (n=6); ** and *** indicate significant differences of p,0.01 and p,0.001,
respectively, compared with the control-treated group.
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Macrophages predominate in the chronic inflammation
phase and are generally considered to be the primary
inflammatory cells involved in the formation of granulation
tissue (36). In addition, macrophages appear to be the
principal source of the cytokines, such as IL-1 and TNF-a,
that are required for the formation of granulation tissue (36).
Previous reports and experimental evidence have shown
that EPMC has a significant ability to suppress cytokine
production, suggesting that it could be useful for inhibiting
angiogenesis. However, its antiangiogenic properties had not
been investigated using standard experimental protocols.
Accordingly, in this study, a series of antiangiogenic assays
were performed to evaluate the antiangiogenic potential of
EPMC, and it was observed that EPMC inhibited the
sprouting and growth of microvessels in rat aortas.
In the present work, EPMC exerted a considerable
inhibitory effect on the sprouting of microvessels from rat
aortas. Further investigation revealed that the anti-angio-
genic effect of EPMC was mediated by the blocking of vital
functions of endothelial cells. It is well known that
antiangiogenic agents can act via direct or indirect inhibi-
tory mechanisms. Direct angiogenesis inhibitors interfere
with endothelial cell functions, such as proliferation,
migration, and differentiation. During the process of
angiogenesis, a single layer of endothelial cells lining the
inside of blood vessels divides and breaks off from the
vessel membrane, forming the tubes and eventually
becoming new capillaries (26). EPMC effectively inhibited
the principal features of angiogenesis in endothelial cells,
including proliferation and migration. After migrating into
the perivascular space in blood vessels, HUEVCs undergo
differentiation. During this process, the cells assume a
characteristic shape, which facilitates intercellular adher-
ence and the formation of a lumen or tube-like structure
(27). EPMC remarkably inhibited the formation of such
tube-like structures in a dose-dependent manner (Figure 4).
These results are also in agreement with those of a recent
study that showed that trans-ethyl-p-methoxycinnamate
was a potent antiangiogenic constituent (37). Additionally,
EPMC inhibited VEGF, which is a key factor required for
angiogenesis (21). Like its anti-inflammatory and analgesic
effects, the anti-angiogenic property of EPMC can also be
attributed to its suppression of cytokines (IL-1 and TNF-a)
and angiogenic mitogens (VEGF), which are important for
the activation of pro-angiogenic pathways.
The results of the present study indicate that ethyl-p-
methoxycinnamate (EPMC) isolated from K. galanga pos-
sesses significant anti-inflammatory and analgesic effects.
The main mechanism of this activity involves inhibition
of the de novo synthesis of pro-inflammatory cytokines,
including TNF-a and IL-1. EPMC exhibited a profound anti-
angiogenic effect in the rat aortic ring assay. This effect was
found to involve the inhibition of vital functions of
endothelial cells, such as proliferation, migration, and tube
formation, and was due to the inhibition of the synthesis of
vascular endothelial growth factor in the cells. Thus, ethyl-p-
methoxycinnamate could be a potential precursor for the
development of therapeutic agents with the potential to
treat diseases involving inflammation and angiogenesis.
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